The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Standardizing MRD techniques after FDA approval as a surrogate endpoint in myeloma trials
Noemi Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, discusses the importance of standardizing techniques for analyzing measurable residual disease (MRD) in multiple myeloma. She highlights the FDA’s approval of MRD as a surrogate for progression-free survival (PFS) in clinical trials, reinforcing its clinical significance. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
